In The Spotlight

From media giants to exclusive industry publications, Humacyte stays in the news.

Humacyte to Present at Oppenheimer 31st Annual Healthcare Conference

Read More

Humacyte to Present Long-Term Follow-Up Data from Phase 2 Vascular Access Trial at Charing Cross (CX) International Symposium 2021

Read More

Humacyte, a Transformative Biotechnology Platform Company Capable of Manufacturing Universally Implantable Bioengineered Human Tissue at Commercial Scale Going Public via Merger with Alpha Healthcare Acquisition Corp.

Read More

Humacyte CEO Dr. Laura Niklason to Present Virtually at ICR Conference Jan 14

Read More

Humacyte CEO Dr. Laura Niklason to Present at J.P. Morgan Healthcare Conference January 11

Read More

Laura Niklason to Speak at Milken Institute Future of Health Summit

Read More

Humacyte Appoints Founder Laura Niklason MD, PhD as President and Chief Executive Officer

Read More

New Paper Defines Breakthroughs in Vascular Tissue Engineering

Read More

Humacyte Founder Laura Niklason, M.D., Ph.D. Elected to National Academy of Engineering

Read More

Humacyte Awarded ‘Large Project Prototype of the Year’ from The Medical Technology Enterprise Consortium

Read More

Science Translational Medicine Publishes Results That Humacyte’s “Human Acellular Vessels Recellularize and Evolve into Living Blood Vessels following Human Implantation”

Read More

Humacyte to Present at the 37th Annual J.P. Morgan Healthcare Conference

Read More

NC Companies Shine At SEBIO Forum

Read More

Humacyte Commences Phase II Vascular Trauma Trial

Read More

Humacyte Appoints Doug Blankenship as Chief Financial Officer

Read More

U.S. Kidney Patients Help Drive Care Innovation Patient insights Accelerate Research and Development

Read More

Humacyte Appoints Jeffrey Lawson MD, PhD as President and Chief Executive Officer

Read More

Fresenius Medical Care and Humacyte announce strategic global partnership supported by a $150M equity investment

Read More

Humacyte Closes $75 Million Series C Financing

Read More

Humacyte Awarded $3.4 Million Contract Award from The U.S. Department of Defense

Read More

Humacyte Receives $14.1 Million Award from California Institute for Regenerative Medicine to Expand Clinical Applications of HUMACYL®

Read More

Humacyte Receives Award from the Medical Technology Enterprise Consortium

Read More

Humacyte Completes Patient Enrollment for Phase III Clinical Trial of Human Acellular Vessel

Read More

Humacyte® Selected as 2017 Technology Pioneer by World Economic Forum

Read More

Awards & Acknowledgments

Coming to a city near you.

Scroll to Top